# US 2022/0008422 A1 · Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008422 A1
- Document ID: US20220008422A1
- Status: Published application
- Kind: A1
- Application number: 17/369,203
- Filed: 2021-07-07
- Published: 2022-01-13
- Earliest claimed: 2020-07-07
- Assignees: Tosk, Inc.
- Applicants: Tosk, Inc.
- Inventors: William A. Garland; Philip Liaw; Brian D. Frenzel
- Web page: https://patentgrep.com/patent/US20220008422A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.

## Claims

### Claim 1

A method of treating a subject for a pulmonary condition having a toxic lung pathology, the method comprising:
administering to the subject an effective amount of a 2,2′-anhydropyrimidine or derivative thereof to treat the subject for the pulmonary condition.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the 2,2′-anhydropyrimidine or derivative thereof is a compound of formula (I):
or the pharmaceutically acceptable salts, solvates, hydrates, and prodrug forms thereof, and stereoisomers thereof;
wherein:
each R1, R2, R3 and R4 is independently selected from the group consisting of hydrogen, substituted or unsubstituted heteroatom, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, carbohydrate, nucleic acid, amino acid, peptide, dye, fluorophore and polypeptide.

### Claim 3 (depends on 2)

The method according to claim 2, wherein each R1, R2, R3 and R4 is independently selected from the group consisting of hydrogen, hydroxyl, sulfyhydryl, amino, hydroxymethyl, methoxy, halogen, pseudohalogen, and a substituted or unsubstituted lower hydrocarbon containing 1 to 20 carbons.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the lower hydrocarbon is selected from the group consisting of alkyl, alkenyl, alkanoyl, aryl, aroyl, aralkyl and alkylamino, and esters thereof.

### Claim 5 (depends on 2)

The method according to claim 2, wherein R1 is hydrogen, fluorine, methyl, ethyl, propyl, benzyl, or 2-bromovinyl; R2 is hydrogen, hydroxyl fluorine, methyl, ethyl, propyl, benzyl, benzoyl, benzoyloxy, or 2-bromovinyl; and each R3 and R4 is independently selected from the group consisting of hydroxyl and benzoyloxy.

### Claim 6 (depends on 5)

The method according to claim 5, wherein R1 is hydrogen or methyl; R2 is hydrogen; and each R3 and R4 is independently selected from the group consisting of hydroxyl and benzoyloxy.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the 2,2′-anhydropyrimidine or derivative thereof is selected from the group consisting of: 2,2′-anhydro-5-methyluridine; 3′-O-benzoyl-2,2′-anhydrouridine; 3′-O-benzoyl-2,2′-anhydro-5-methyluridine; 5′-O-benzoyl-2,2′-anhydrouridine; and 5′-O-benzoyl-2,2′-anhydro-5-methyluridine.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the 2,2′-anhydropyrimidine or derivative thereof is 2,2′-anhydro-5-methyluridine.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the 2,2′-anhydropyrimidine or derivative thereof is 3′-O-benzoyl-2,2′-anhydro-5-methyluridine.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the 2,2′-anhydropyrimidine or derivative thereof is 5′-O-benzoyl-2,2′-anhydro-5-methyluridine.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the 2,2′-anhydropyrimidine or derivative thereof comprises a stereoisomer.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the stereoisomer is selected from the group consisting of 2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil; 3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-uracil; 3′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil; 5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-uracil; and 5′-O-benzoyl-2,2′-anhydro-1-(β-D-arabinofuranosyl)-5-methyluracil.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the 2,2′-anhydropyrimidine or derivative thereof is administered to the subject suffering NAFLD.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the 2,2′-anhydropyrimidine or derivative thereof is administered to the subject suffering NASH.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the 2,2′-anhydropyrimidine or derivative thereof is administered to the subject suffering a DILI.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the 2,2′-anhydropyrimidine or derivative thereof is administered to the subject likely to suffer a DILI because of planned treatment.

### Claim 17

A method of treating a subject for pulmonary condition having a toxic hepatic pathology, the method comprising:
administering to the subject an effective amount of a 2,2′-anhydropyrimidine or derivative thereof in combination with one or more of UR, an UR prodrug and an UR mimetic to treat the subject for the pulmonary condition.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the 2,2′-anhydropyrimidine or derivative thereof is a compound of formula (I):
or the pharmaceutically acceptable salts, solvates, hydrates, and prodrug forms thereof, and stereoisomers thereof;
wherein:
each R1, R2, R3 and R4 is independently selected from the group consisting of hydrogen, substituted or unsubstituted heteroatom, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, carbohydrate, nucleic acid, amino acid, peptide, dye, fluorophore and polypeptide.

### Claim 19 (depends on 18)

The method according to claim 18, wherein each R1, R2, R3 and R4 is independently selected from the group consisting of hydrogen, hydroxyl, sulfyhydryl, amino, hydroxymethyl, methoxy, halogen, pseudohalogen, and a substituted or unsubstituted lower hydrocarbon containing 1 to 20 carbons.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the lower hydrocarbon is selected from the group consisting of alkyl, alkenyl, alkanoyl, aryl, aroyl, aralkyl and alkylamino, and esters thereof.

### Claim at position 21

21-44. (canceled)
